Quantitation of amyloid-beta peptides in biological milieu using a novel HTRF assay

Research Highlights Life Science

Development of HTRF Ab( 1-40) and (1-42) assay using custom antibody labelling with EuK

Expert opinion

Description of HTRF Ab( 1-40) and (1-42) assay development is described. Using custom antibody labelling with EuK (study by Merck).


Many of the recent advances in the understanding of the pathological processes underlying Alzheimer’s disease have come about as a result of the development of assays that can specifically quantitate in biological milieu amyloid-beta (A beta) peptides ending at amino-acid positions Ala-42 (A beta(42)) and Val-40 (A beta(40)). The existing technologies, however, although proven in their utility are limited in their application with regards to sample manipulation and suitability for high-throughput screening. To overcome these limitations, in this report we describe the development of a novel homogeneous time-resolved fluorescence (HTRF) immunoassay for A beta(42) and A beta(40) peptides. This assay has the sensitivity, selectivity and dynamic range to allow specific, direct quantitation of A beta peptides in cell culture medium, plasma, cerebrospinal fluid and brain tissue extracts, and has the major advantage of minimising sample manipulation and its inherent inaccuracies.


J Neurosci Methods. 2000;102(1):61-8.

Read on PUBMED